MD FRCP (UK), Senior Vice President, Global Chief Medical Officer, joined Novo Nordisk A/S, as Senior Principal Clinical Scientist in Copenhagen, Denmark in 2015 in the Chief Medical Office, to provide advice and clinical guidance on the development of new molecules and drugs, from early through to phase III and beyond, for the treatment of diabetes and obesity. In 2018, Stephen became Senior Vice President and Global Chief Medical Officer.
Prior to joining Novo Nordisk, Stephen was Head of the Oxford Centre for Diabetes Endocrinology and Metabolism (OCDEM), in the UK and served as Professor of Diabetes to the University of Oxford and Consultant Physician at the Oxford University of Hospitals NHS Trust. He was also the Diabetes Clinical Lead for the Local Clinical Research Network and the Academic Health Science Network in Oxford.
His research interests have resided in the fields of the genetics of autoimmune disease, glucose homeostasis, incretin biology in pancreas whole organ and islet transplantation, and clinical trials of GLP-1 based therapies. Since joining Novo Nordisk he has supported a number of activities and provided senior medical opinion in diabetes, obesity and biopharm.